William Blair analyst Brian Weinstein downgrades 10x Genomics (NASDAQ:TXG) from Outperform to Market Perform.
Nvidia CEO Says China Hyperscalers Really Slowed Down Infrastructure Investment, Big Slow Down In Q2
-Reuters Citing Conference Call
William Blair Downgrades 10x Genomics to Market Perform
William Blair analyst Brian Weinstein downgrades 10x Genomics (NASDAQ:TXG) from Outperform to Market Perform.
Related Posts
Office Depot Parent ODP Boosts FY24 EPS Outlook Despite Bumpy Q1 Ride: Details
Dive into the latest earnings report of ODP Corporation. Despite a sales decline in Q1 FY24, the company saw a significant rise in gross profit. Find out the key factors influencing its financial performance and CEO Gerry Smith's insights on the challenges faced.
Truist Securities Maintains Buy on Boston Scientific, Raises Price Target to $54
Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:BSX) with a Buy and raises the price target from $50 to $54.
Recession Investing: 5 High Yield Dividend Stocks For A Downturn
As the healthcare industry absorbed enormous amounts of profits during the Covid-19 pandemic, many healthcare companies will be increasing shareholder distributions to entice investors to buy their stock.